International Myeloma Society https://validator.w3.org/feed/docs/rss2.html International Myeloma Society: ASCO and EHA Signal a Pivotal Moment in Multiple Myeloma Research IMS Connect IMS Connect – June 12, 2026 IMS Connect – June 5, 2026 IMS Connect – June 5, 2026 IMS Connect – May 29, 2026 IMS Connect – May 22, 2026 IMS Connect – November 28, 2025 IMS Connect – November 21, 2025 IMS Connect – November 14, 2025 IMS Connect – May 8, 2026 IMS Connect – May 1, 2026 IMS Connect – March 6, 2026 IMS Connect – March 27, 2026 IMS Connect – March 20, 2026 IMS Connect – March 13, 2026 IMS Connect – January 9, 2026 IMS Connect – January 30, 2026 IMS Connect – January 23, 2026 IMS Connect – January 2, 2026 IMS Connect – January 16, 2026 IMS Connect – February 6, 2026 IMS Connect – February 27, 2026 IMS Connect – February 20, 2026 IMS Connect – February 13, 2026 IMS Connect – December 5, 2025 IMS Connect – December 19, 2025 IMS Connect – December 12, 2025 IMS Connect – April 3, 2026 IMS Connect – April 24, 2026 IMS Connect – April 17, 2026 IMS Connect – April 10, 2026 IMS Connect – May 15, 2026 IMS News Room International Myeloma Society Opens Abstract Submissions for 23rd Annual Meeting International Myeloma Society Launches National Webinar Series to Support Community Use of Emerging Immunotherapies in Multiple Myeloma International Myeloma to Convene Global Experts in Warsaw for 4th Annual Workshop on Genomics Home Improving Prognosis of Progression Risk in Multiple Myeloma Precursors through Single Cell Sequencing-Based Genomic and Immune Microenvironment Profiling Functional screens on single-cell transcriptomes of genotypically-defined minimal residual disease cells to unravel specific vulnerabilities of treatment resistant multiple myeloma (FUTURE) Comprehensive genomic and immune characterization of response and resistance to daratumumab-based quadruplet induction therapy Targeting inter-organelle communication to arrest multiple myeloma Investigating heme-induced effector CAR T cells for multiple myeloma therapy Comprehensive Exploration of Molecular Pathways and Biomarkers in Myeloma-Induced Bone Disease: A Multi-Omics Approach for Personalized Therapeutic Management iMMagine Dissect the mechanisms by which CST6N137D enhances the efficacy of CAR-T cell therapy in myeloma Targeting Collagen-LAIR1 for Improving Multiple Myeloma Therapeutic Efficacy SHIELD-MM – A modular multiplex shRNA platform to enhance functional persistence of academic anti-BCMA CAR-T cells (ARI0002h) in multiple myeloma. Targeting TCF3 addiction in multiple myeloma Exploiting translation control vulnerabilities imposed by antibody secretion in multiple myeloma